Receive an award for an Artificial Intelligence development.
KeyZell promotes its cancer treatments and for this it has received an award in the II Edition of the Isaac Peral National Research, Science and Innovation Awards organized by the European Association of Economy and Competitiveness for the development of Artificial Intelligence.
These awards recognize the research work carried out by the biotech startup in the development of Artificial Intelligence capable of recommending personalized treatments for lung and breast cancer to medical professionals .
This “startup” is distinguished by attacking cancer from two fronts, research into first-line cancer treatments and the use of AI technology for precision medicine in oncology (Oncology Precision System).
The awards also recognized the work of professionals such as Dr. Elisabeth Arrojo Álvarez, Medical Director of the Medical Institute of Advanced Oncology (Inmoa) , who was distinguished for her professional research career in the oncology world, highlighting the development of a pioneering technique in breast cancer that shortens the number of radiotherapy sessions from more than 30 daily sessions to a single session.
The European Association of Economy and Competitiveness awards the merit of researchers who carry out outstanding work in scientific fields and who contribute to the advancement of science, better knowledge of the human being, technology transfer and the progress of humanity.
Likewise, it distinguishes those entities that have made innovation an indispensable element in business development and growth, demonstrating a powerful lever for innovation and competitiveness.
Backed by an internationally renowned management and research team, KeyZell helps oncologists make more accurate decisions by enabling personalized medicine, reducing recurrence, overmedication, hospitalization time, treatment costs, follow-up through of all clinical phases, and, above all, it has a positive impact on the quality of life of patients.
In addition, it is preparing a Token Generation Event (TGE) with an issuance of 2 billion tokens and 200,000 NFTs.
This token issue is a risk-free investment despite the current destabilization of the crypto market, since it is backed by the company’s own value, meaning that this investment is not merely speculative and does not depend on market value.
With this issue, KeyZell intends to continue advancing in its project to fight cancer and operate in a secure environment, since they work under “blockchain” technology.